Blog

Injection offers hope for asthma and COPD patients: A study in Lancet Respiratory Medicine showcased a promising new treatment for asthma and chronic obstructive pulmonary disease using benralizumab injections, demonstrating that a single injection during flare-ups is more effective than conventional steroid tablets, marking the first major advancement in 50 years. Benralizumab injections reduced the need for additional interventions by 30% and showed fewer symptoms and treatment failures, suggesting that the antibody injection could be a safer alternative to steroids, which have serious side effects.

New schizophrenia drug shows promise for other brain disorders: KarXT, a new schizophrenia drug with a novel mechanism targeting muscarinic receptors, has sparked interest in its potential to treat Alzheimer’s disease, bipolar disorder and addiction, though real-world effectiveness and side effects are concerns. Xanomeline, one of KarXT’s components, primarily affects the M1 and M4 muscarinic receptors, with research showing M4 linked to antipsychotic effects and M1 linked to cognition, prompting researchers to explore targeted therapies that could offer greater benefits with fewer side effects.

Screening urged for iron deficiency to prevent anemia: Screening for iron deficiency in patients with risk factors can prevent progression to conditions such as microcytic anemia, according to a presentation at a family medicine meeting. Nonanemic iron deficiency is common, affecting 38.3% of women of reproductive age, and is linked to hospitalizations and reduced quality of life, according to a study.

Experts urge caution when interpreting incidental findings on mammograms: Some radiology practices are offering to analyze mammograms for breast arterial calcification, a potential indicator of heart disease risk, using AI (Artificial Intelligence). Some studies have found an association between calcification and cardiovascular risk; however, experts urge caution, noting that the correlation is not as strong as with coronary artery calcification and the absence of breast arterial calcification does not necessarily equate to an absence of heart disease.

Mortician turned scientist unlocks secrets of ancient brains: Former wedding planner, dishwasher and mortician Alexandra Morton-Hayward, now a 35-year-old molecular paleontologist at Oxford University, spends a lot of time in medieval graveyards, mass graves and even crime scenes collecting brains from old skulls buried there. In the mid-1990s, archaeologist Sonia O’Connor discovered that some brains remain intact for decades — even centuries — after death, and Morton-Hayward, whose own brain subjects her to severe cluster headaches every night, uses mass spectrometry, particle accelerators and other advanced technologies to determine how, potentially reshaping our understanding of neurodegenerative conditions.

Parents advocate for newborn genetic screening initiative: Jessica and Pete Williams enrolled their newborn son in the Generations Study at The Rosie Hospital, Cambridge, England to screen his DNA for 200 rare but treatable genetic conditions, and they are advocating for other parents to participate. Led by Genomics England, the study may involve up to 100,000 newborns across England, enabling early disease detection while deepening our understanding of the genetic links to various conditions.

Gene therapy shows promise for neurologic disease: Six (6) years after receiving “eli-cel” gene therapy for the genetic condition cerebral adrenoleukodystrophy, most of the 77 boys treated remained free of disability, according to a study published in The New England Journal of Medicine. However, in a second study, 6 of 35 boys who were treated with one form of the gene therapy developed blood cancer.

Genes tied to epilepsy identified in largest such study: In a sweeping study by 40 scientific teams from around the world, individual genes, gene sets, and gene variants that raise people’s risk of developing epilepsy have been identified using whole-exome sequencing of DNA to compare the genes of 20,979 people with epilepsy to those of 33,444 people without the condition. This is the biggest research effort of its kind, published in Nature Neuroscience, and it could lead to better diagnosis and treatment for epilepsy, a neurological disorder that affects 4 to 10 in 1,000 individuals.

What a difference a week makes. After hundreds of FDA employees were suddenly laid off last weekend — including dozens at the Agency’s device center tasked with reviewing products for clearance and approval — the government has begun rescinding some of those cuts and attempting to rehire lost workers.

While the FDA’s Diversity Guidance for clinical trials has been temporarily restored, the page it is housed on now carries a message from the Trump administration that the guidance “does not reflect biological reality.”